Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 86
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03860883 | Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | ||
| NCT00812669 | CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | ||
| NCT02050750 | TAILORx Tissue Bank | ||
| NCT02219178 | Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | ||
| NCT00974168 | Spinal Cord Compression Re-Treat Study | ||
| NCT01495884 | The Myocet/Lapatinib Study. ICORG 10-03, V5 | ||
| NCT01658930 | Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer | ||
| NCT02177110 | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma | ||
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | ||
| NCT00968682 | CADY Study ICORG 08-01 | ||
| NCT01722890 | CharactHer. ICORG 12-09, V3 | ||
| NCT01485926 | A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | ||
| NCT00809211 | Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | ||
| NCT00802711 | 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer | ||
| NCT02160353 | Neo-adjuvant Abiraterone Prostate Study | ||
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | ||
| NCT00974610 | Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. | ||
| NCT01822444 | ANGIOPREDICT. ICORG 12-16, V3 | ||
| NCT01840293 | Breast Cancer Proteomics and Molecular Heterogeneity | ||
| NCT04375904 | 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) | ||
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | ||
| NCT00955435 | Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15 | ||
| NCT02050737 | Plasma Biomarkers C-RAC, ICORG 12-27, V1 | ||
| NCT00513877 | Bortezomib in Treating Patients With Malignant Pleural Mesothelioma | ||
| NCT06078813 | Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases | ||
| NCT02050997 | Plasma Biomarkers P-DAC, V1 | ||
| NCT00968643 | Spinal Cord Compression. ICORG 05-03, V6 | ||
| NCT00470236 | Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast | ||
| NCT01176487 | Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34 | ||
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | ||
| NCT01840306 | Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer | ||
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) | ||
| NCT05974774 | Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors | ||
| NCT01158287 | Sorafenib. ICORG 06-41, V4 | ||
| NCT00962312 | Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer | ||
| NCT03843346 | The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer | ||
| NCT06274541 | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study | ||
| NCT01726322 | Ovarian Reserve in Premenopausal Breast Cancer | ||
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | ||
| NCT02836392 | CRQ Survey Study: Clinical Research Questionnaire of Oncology Patients - A Nationwide Survey | ||
| NCT03698201 | Blood Biomarker Signature in Glioma | ||
| NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | ||
| NCT06149546 | Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial) | ||
| NCT01710592 | A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer | ||
| NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | ||
| NCT02950051 | Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation | ||
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | ||
| NCT00814541 | PAD. ICORG 05-01, V11 | ||
| NCT04581070 | The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic" | ||
| NCT02582697 | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours |
